Baricitinib (LY3009104) 4 mg

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Cardiac Sarcoidosis

Conditions

Cardiac Sarcoidosis

Trial Timeline

Apr 1, 2026 → Dec 1, 2028

NCT ID

NCT06868381

About Baricitinib (LY3009104) 4 mg

Baricitinib (LY3009104) 4 mg is a phase 2 stage product being developed by Eli Lilly for Cardiac Sarcoidosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06868381. Target conditions include Cardiac Sarcoidosis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06868381	Phase 2	Recruiting	Apr 1, 2026	Dec 1, 2028	Cardiac Sarcoidosis

Competing Products

20 competing products in Cardiac Sarcoidosis

See all competitors

Product	Company	Stage	Hype Score
Edoxaban + Standard of Care (SOC)	Daiichi Sankyo	Phase 3	77
regadenoson	Astellas Pharma	Pre-clinical	23
Current Domperidone + Current proton pump inhibitor (PPI)	Johnson & Johnson	Pre-clinical	23
Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin	Merck	Approved	85
Everolimus (RAD001)	Novartis	Phase 3	77
Deferasirox and Deferoxamine	Novartis	Phase 2	52
Everolimus + Mycophenolic acid (MPA)/azathioprine (AZA) + Calcineurin inhibitors (CNI) + Steroids	Novartis	Approved	85
TIN816	Novartis	Phase 2	52
Everolimus + Mycophenolate mofetil + Everolimus	Novartis	Approved	85
Pirfenidone + Placebo	Roche	Phase 2	52
Daclizumab	Roche	Phase 1/2	41
Ranolazine + Placebo	Gilead Sciences	Phase 3	76
Insulin infusion with a goal	Novo Nordisk	Phase 3	76
Epinephrine	Pfizer	Approved	84
sitaxsentan (Thelin) + sitaxsentan (Thelin) + Placebo	Pfizer	Phase 2	51
Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)	Mochida Pharmaceutical	Approved	84
BMS-986224	Bristol Myers Squibb	Phase 1	32
BMS-986231 + Furosemide + Placebo	Bristol Myers Squibb	Phase 2	51
Balinatunfib + Moxifloxacin + Placebo	Sanofi	Phase 1	32
Sotagliflozin + Placebo	Sanofi	Phase 2	51

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved